<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866319</url>
  </required_header>
  <id_info>
    <org_study_id>3475-006</org_study_id>
    <secondary_id>2012-004907-10</secondary_id>
    <secondary_id>MK-3475-006</secondary_id>
    <nct_id>NCT01866319</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)</brief_title>
  <official_title>A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of 2 different dosing schedules of
      pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2
      schedules to treatment with ipilimumab in ipilimumab-naïve participants with unresectable or
      metastatic melanoma. The primary hypotheses are that pembrolizumab is superior to ipilimumab
      with respect to progression-free survival (PFS) and overall survival (OS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants assigned to a primary course of pembrolizumab can receive up to 24 months of
      treatment. Participants with Stable Disease (SD) or better will then proceed to Post
      Treatment Follow-up. All efficacy and safety analyses will be based on the primary
      pembrolizumab course.

      Participants who experience disease progression during the Post Treatment Follow-up will be
      eligible for a Second Course of pembrolizumab treatment for up to 1 additional year. With
      Amendment 05, all Second Course participants will be treated with a fixed dose of
      pembrolizumab 200 mg Q3W. With Amendment 06, after the study has achieved its key objectives
      or the study has ended, participants will be discontinued from this study and enrolled in an
      extension study to continue protocol-defined assessments and treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2013</start_date>
  <completion_date type="Actual">June 3, 2019</completion_date>
  <primary_completion_date type="Actual">March 3, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)</measure>
    <time_frame>Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded Independent Radiology plus Oncology review (IRO) using RECIST 1.1, or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of new lesions. The primary analysis of PFS was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS) at 12 Months</measure>
    <time_frame>Month 12</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. The percentage of participants with OS (OS rate) at 12 months was reported for each arm. The reported percentage was estimated using a product-limit (Kaplan-Meier) method for censored data; data were censored at the date of cut-off. The primary analysis of OS was performed at the time of the second protocol pre-specified statistical analysis, with data cut-off of 03-Mar-2015.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by IRO</measure>
    <time_frame>Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)</time_frame>
    <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR: disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm) or partial response (PR: ≥30% decrease in the sum of diameters of target lesions), based on IRO using RECIST 1.1. The primary analysis of ORR was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">834</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Q3W</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>10 mg/kg IV, administered Q2W or Q3W based upon randomization.</description>
    <arm_group_label>Pembrolizumab Q2W</arm_group_label>
    <arm_group_label>Pembrolizumab Q3W</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>3 mg/kg IV Q3W.</description>
    <arm_group_label>Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed diagnosis of unresectable Stage III or metastatic melanoma
             not amenable to local therapy (excluding uveal or ocular melanoma)

          -  At least one measurable lesion

          -  No prior systemic treatment (excluding adjuvant or neoadjuvant therapy) for melanoma
             (first line) or one prior systemic treatment (excluding adjuvant or neoadjuvant
             therapy) for melanoma (second line)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Archived tissue sample or new biopsy sample

          -  Female participants of childbearing potential must agree to use effective
             contraception from Visit 1 to 120 days after the last dose of study drug; male
             participants must agree to use an adequate method of contraception starting with the
             first dose of study drug through 120 days after the last dose of study drug

        Exclusion criteria:

          -  Prior treatment with ipilimumab or other anti-cytotoxic T-Lymphocyte Antigen 4
             (CTLA-4) agent or any anti-programmed cell death (PD-1 or PD-L2) agent

          -  Chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the
             first dose of study drug, or not recovered from adverse events caused by cancer
             therapeutics administered more than four weeks earlier

          -  Currently participating or has participated in a study of an investigational agent or
             using an investigational device within 30 days of the first dose of study drug

          -  Expected to require any other form of systemic or localized antineoplastic therapy
             while on study

          -  On any systemic steroid therapy within one week before the planned date for first dose
             of randomized treatment or on any other form of immunosuppressive medication

          -  History of a malignancy (other than the disease under treatment in the study) within 5
             years prior to first study drug administration, excluding adequately treated Stage 1
             or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the cervix
             or breast, or other in situ cancers.

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             participants with previously treated brain metastases are eligible

          -  Severe hypersensitivity reaction to treatment with another monoclonal antibody

          -  Active autoimmune disease or a documented history of autoimmune disease or syndrome
             that requires systemic steroids or immunosuppressive agents

          -  Active infection requiring systemic therapy

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Known history of or positive for Hepatitis B or C

          -  Known psychiatric or substance abuse disorder

          -  Regular user (including recreational use) of illicit drugs or had a recent history
             (within the last year) of substance abuse (including alcohol)

          -  Pregnant or breastfeeding, or expecting to conceive, or father children within the
             projected duration of the study

          -  Received a live vaccine within 30 days prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <reference>
    <citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.</citation>
    <PMID>25891173</PMID>
  </reference>
  <results_reference>
    <citation>Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.</citation>
    <PMID>28822576</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>December 9, 2015</results_first_submitted>
  <results_first_submitted_qc>December 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2016</results_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=3475-006&amp;kw=3475-006&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with advanced melanoma were recruited to receive ipilimumab once every 3 weeks (Q3W), or a primary course of pembrolizumab administered every 2 weeks (Q2W) or every 3 weeks (Q3W).</recruitment_details>
      <pre_assignment_details>834 participants were randomized 1:1:1 to receive ipilimumab Q3W, pembrolizumab Q2W, or pembrolizumab Q3W. For participants receiving pembrolizumab, all safety and efficacy results data reported are for the primary pembrolizumab course received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ipilimumab</title>
          <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
        </group>
        <group group_id="P2">
          <title>Pembrolizumab Q2W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
        </group>
        <group group_id="P3">
          <title>Pembrolizumab Q3W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) population consisted of all randomized participants. Participants were included in the group to which they were randomized for Baseline Characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Ipilimumab</title>
          <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
        </group>
        <group group_id="B2">
          <title>Pembrolizumab Q2W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Pembrolizumab Q3W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="278"/>
            <count group_id="B2" value="279"/>
            <count group_id="B3" value="277"/>
            <count group_id="B4" value="834"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="14.2"/>
                    <measurement group_id="B2" value="59.9" spread="14.6"/>
                    <measurement group_id="B3" value="61.2" spread="13.6"/>
                    <measurement group_id="B4" value="60.3" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="337"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)</title>
        <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded Independent Radiology plus Oncology review (IRO) using RECIST 1.1, or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of new lesions. The primary analysis of PFS was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
        <time_frame>Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)</time_frame>
        <population>The ITT population, comprising all participants as randomized to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)</title>
          <description>PFS was defined as the time from randomization to the first documented disease progression, based on blinded Independent Radiology plus Oncology review (IRO) using RECIST 1.1, or death due to any cause, whichever occurred first. Disease progression was defined as a 20% or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of new lesions. The primary analysis of PFS was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
          <population>The ITT population, comprising all participants as randomized to a study arm.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="3.4" upper_limit="6.9"/>
                    <measurement group_id="O3" value="4.1" lower_limit="2.9" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), programmed cell death ligand 1 (PD-L1) status (positive vs. negative) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.75869</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Overall Survival (OS) at 12 Months</title>
        <description>OS was defined as the time from randomization to death due to any cause. The percentage of participants with OS (OS rate) at 12 months was reported for each arm. The reported percentage was estimated using a product-limit (Kaplan-Meier) method for censored data; data were censored at the date of cut-off. The primary analysis of OS was performed at the time of the second protocol pre-specified statistical analysis, with data cut-off of 03-Mar-2015.</description>
        <time_frame>Month 12</time_frame>
        <population>The ITT population, comprising all participants as randomized to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS) at 12 Months</title>
          <description>OS was defined as the time from randomization to death due to any cause. The percentage of participants with OS (OS rate) at 12 months was reported for each arm. The reported percentage was estimated using a product-limit (Kaplan-Meier) method for censored data; data were censored at the date of cut-off. The primary analysis of OS was performed at the time of the second protocol pre-specified statistical analysis, with data cut-off of 03-Mar-2015.</description>
          <population>The ITT population, comprising all participants as randomized to a study arm.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="51.8" upper_limit="64.0"/>
                    <measurement group_id="O2" value="74.1" lower_limit="68.5" upper_limit="78.9"/>
                    <measurement group_id="O3" value="68.4" lower_limit="62.5" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.00052</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.00358</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1).</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.51319</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by IRO</title>
        <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR: disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm) or partial response (PR: ≥30% decrease in the sum of diameters of target lesions), based on IRO using RECIST 1.1. The primary analysis of ORR was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
        <time_frame>Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)</time_frame>
        <population>The ITT population, comprising all participants as randomized to a study arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab Q2W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Pembrolizumab Q3W</title>
            <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by IRO</title>
          <description>ORR was defined as the percentage of the participants with a best tumor response of complete response (CR: disappearance of all target lesions with any pathological lymph nodes having a reduction in short axis to &lt;10 mm) or partial response (PR: ≥30% decrease in the sum of diameters of target lesions), based on IRO using RECIST 1.1. The primary analysis of ORR was performed at the time of the first protocol pre-specified statistical analysis, with data cut-off of 03-Sep-2014.</description>
          <population>The ITT population, comprising all participants as randomized to a study arm.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="8.3" upper_limit="16.3"/>
                    <measurement group_id="O2" value="33.7" lower_limit="28.2" upper_limit="39.6"/>
                    <measurement group_id="O3" value="32.9" lower_limit="27.4" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.00013</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>16.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.8</ci_lower_limit>
            <ci_upper_limit>24.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.00002</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>25.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical testing was stratified by line of therapy (1st vs. 2nd), PD-L1) status (positive vs. negative) and ECOG performance status (0 vs. 1)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.82636</p_value>
            <method>Miettinen &amp; Nurmimen</method>
            <param_type>Percent difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 69 months (through End of Trial Analysis data cut-off date of 03-Jun-2019)</time_frame>
      <desc>All-Cause Mortality table includes all randomized participants.
Serious and Other adverse events (AEs) tables include all randomized participants who received at least 1 dose of study drug. Per protocol, disease progression of cancer on study was not considered an AE unless considered related to study drug. Therefore, MedDRA preferred terms &quot;Neoplasm progression&quot;, &quot;Malignant neoplasm progression&quot; and &quot;Disease progression&quot; not related to study drug are excluded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ipilimumab</title>
          <description>Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).</description>
        </group>
        <group group_id="E2">
          <title>Pembrolizumab Q2W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.</description>
        </group>
        <group group_id="E3">
          <title>Pembrolizumab Q3W</title>
          <description>Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anaemia aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymph nodes enlarged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Congestive cardiac failure aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Decompensation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Heart attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Adrenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Panhypopituitarism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neovascular glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Autoimmune pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blood in stool</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="256"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhage of digestive tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Mouth necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pancreatitis aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Partial small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>General body pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Reduced general condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Unknown cause of death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug-induced hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatic cytolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Obstructive jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypersensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis of oral soft tissues</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cellulitis of upper arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Septicaemia gram-negative NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Shoulder injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Wound breakdown</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bilirubin total increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intraocular pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hyponatremia aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hips osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in heel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pathologic fracture of femur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pathologic fracture of humerus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Prolapsed lumbar disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Psoriatic arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Seronegative arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Unilateral leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Basal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Desmoplastic melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Epidermoid carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Huerthle cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intra-epidermal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intracranial tumour bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastases to brain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Signet-ring cell adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Superficial basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thyroid papillary carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tumour bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bell's palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebral oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Convulsions aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhage brain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Horner's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Paraneoplastic limbic encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vasogenic cerebral oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Autoimmune nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nephritis interstitial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea exacerbated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bullous lichen planus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bullous pemphigoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drug rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Thrombosis leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="247" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" events="44" subjects_affected="34" subjects_at_risk="278"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="256"/>
                <counts group_id="E2" events="78" subjects_affected="53" subjects_at_risk="278"/>
                <counts group_id="E3" events="47" subjects_affected="39" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="91" subjects_affected="69" subjects_at_risk="256"/>
                <counts group_id="E2" events="162" subjects_affected="82" subjects_at_risk="278"/>
                <counts group_id="E3" events="116" subjects_affected="76" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="66" subjects_affected="55" subjects_at_risk="256"/>
                <counts group_id="E2" events="90" subjects_affected="73" subjects_at_risk="278"/>
                <counts group_id="E3" events="88" subjects_affected="70" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="256"/>
                <counts group_id="E2" events="66" subjects_affected="45" subjects_at_risk="278"/>
                <counts group_id="E3" events="32" subjects_affected="27" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="256"/>
                <counts group_id="E2" events="92" subjects_affected="45" subjects_at_risk="278"/>
                <counts group_id="E3" events="56" subjects_affected="41" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="78" subjects_affected="73" subjects_at_risk="256"/>
                <counts group_id="E2" events="125" subjects_affected="90" subjects_at_risk="278"/>
                <counts group_id="E3" events="116" subjects_affected="85" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="256"/>
                <counts group_id="E2" events="40" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="35" subjects_affected="21" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" events="27" subjects_affected="14" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" events="43" subjects_affected="31" subjects_at_risk="278"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" events="35" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="25" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E3" events="28" subjects_affected="26" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="256"/>
                <counts group_id="E2" events="39" subjects_affected="31" subjects_at_risk="278"/>
                <counts group_id="E3" events="36" subjects_affected="35" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E2" events="34" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" events="63" subjects_affected="41" subjects_at_risk="278"/>
                <counts group_id="E3" events="42" subjects_affected="39" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="278"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="256"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="256"/>
                <counts group_id="E2" events="72" subjects_affected="45" subjects_at_risk="278"/>
                <counts group_id="E3" events="58" subjects_affected="33" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="278"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" events="75" subjects_affected="58" subjects_at_risk="278"/>
                <counts group_id="E3" events="48" subjects_affected="43" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="76" subjects_affected="65" subjects_at_risk="256"/>
                <counts group_id="E2" events="99" subjects_affected="68" subjects_at_risk="278"/>
                <counts group_id="E3" events="83" subjects_affected="59" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="256"/>
                <counts group_id="E2" events="55" subjects_affected="37" subjects_at_risk="278"/>
                <counts group_id="E3" events="51" subjects_affected="36" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="278"/>
                <counts group_id="E3" events="45" subjects_affected="42" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

